Biotech Values

[mcbio]

ARRY - Analyst Day CC notes (12/16/11)

[FWIW, I only listened to the first hour of this CC related to ARRY's MEK inhibitors, and not the latter portion that is supposed to be devoted to ARRY-520 and ARRY-614, insofar as it's the MEK inhibitors that I view as the key potential future value drivers for ARRY.]

1. Slide 14 - MEK pathway mutations:

(a) BRAF melanoma - 43%;
(b) GNAQ/GNA11 ocular melanoma - 59%;
(c) KRAS NSCLC - 16%;
(d) KRAS pancreatic - 57%; and
(e) KRAS colorectal - 35%.

2. Buzz for MEK+PI3K/Akt inhibitor or MEK+taxanes.

3. Slide 26 - BRAF mutant melanoma data

(a) Vemurafenib Phase 3 data - ORR = 48% and mPFS = 5.3 months
(b) selumetinib + DTIC Phase 1b data - ORR = 56% and mPFS = 7.1 months

4. Slide 27 - KRAS NSCLC data

ARQ197 + erlotinib only showed 2.3 months mPFS in 2nd-line KRAS NSCLC patients . Same for sorafenib single agent.

5. 38 minute mark - In regards to the MEK162 Phase 1 expansion trial in biliary tract cancer patients, ARRY will be presenting results at ASCO GI in January where ARRY has seen PRs and CRs in single-agent trials of MEK162 in a heavily pre-treated patient population. (Someone please listen to the 38 minute mark and let me know if my ears have deceived me; seems pretty clear to me that the presenter said there have been both PRs and CRs seen in this trial. It is of course possible that he misspoke.)